The struggle to do no harm

The Outlook article ‘The struggle to do no harm’ (Nature 552, S74–S75; 2017) mistakenly claimed that the biopharmaceutical firm Cellectis had not responded to requests for interview. A comment from the company is now included in the online version of the story.

Nature 554, 31 (2018)

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.